Genfit S.A. (GNFT)

Market Cap	178.38M
Revenue (ttm)	42.42M
Net Income (ttm)	-32.10M
Shares Out	49.69M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	6.17
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,488
Open	3.460
Previous Close	3.460
Day's Range	3.450 - 3.630
52-Week Range	2.894 - 4.750
Beta	0.87
Analysts	Strong Buy
Price Target	11.00 (+206.41%)
Earnings Date	Apr 4, 2024

About GNFT

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 27, 2019
• Employees: 159
• Stock Exchange: NASDAQ
• Ticker Symbol: GNFT

Financial Performance

In 2023, Genfit's revenue was 38.18 million, an increase of 43.70% compared to the previous year's 26.57 million. Losses were -28.89 million, 21.8% more than in 2022.

Financial numbers in EUR

Analyst Forecast

According to one analyst, the rating for GNFT stock is "Strong Buy" and the 12-month stock price forecast is $11.0.

Price Target

$11.0

(206.41% upside)

Analyst Consensus: Strong Buy